A retrospective study on the efficacy and safety of intraveinous immunoglobulin (Tegeline(®)) in patients with chronic inflammatory demyelinating polyneuropathy.

CONCLUSION: This retrospective study confirmed both the efficacy of IV Ig at 4 months in the treatment of chronic inflammatory demyelinating polyneuropathy and the favorable safety profile of the product. PMID: 26071027 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26071027?dopt=Abstract

Source: Presse Medicale - June 9, 2015 Category: Journals (General) Authors: Robert F, Edan G, Nicolas G, Pouget J, Vial C, Antoine JC, Puget S Tags: Presse Med Source Type: research

More News: CIDP | General Medicine | Study